The Cell and Gene Therapy Lab at CHOP has been approved for a phased expansion project that will allow them to keep up with the pace of discovery in a rapidly changing field.
Researchers at CHOP are recruiting patients diagnosed with either acute leukemia (myeloid, lymphoid), myelodysplastic syndromes, or aplastic anemia and treated with allogeneic hematopoietic cell transplantation (HCT) within the past 6-48 months.
The study will enroll male and female patients between 2 years to 25 years of age with sickle cell disease or beta thalassemia major, who do not have a matched related donor, and their doctor feels their condition should be treated with hematopoietic stem cell transplantation (HSCT).
The purpose of this research study is to understand the impact of transplant on the quality of life of the entire family including sibling donors, other siblings and parents.
The Teachey Lab studies perturbations in leukemic cell signal transduction pathways with the aim of identifying targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome.
The purpose of this research study is to test a new method of cell processing for stem cell transplants with an unrelated donor or partially matched related donor for patients with BMF who do not have a well matched related donor.